Novavax

NVAX

Market cap $1.26B

Novavax, Inc. (NVAX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Novavax (NVAX) concluded the recent trading session at $8.19, signifying a -5.54% move from its prior day's close.

Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

GAITHERSBURG, Md., Jan. 7, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the 44th Annual J.P.

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.

Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Novavax faces plenty of uncertainty related to a deal it signed with a larger company. The biotech's pipeline doesn't look that exciting either.

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

A report that vaccine approvals could be set to get stricter is pressuring shares of major vaccine makers.